Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31410710 | 0.87 | ESR2 (0.76) | ESR2PTPN5ALOX5APFEN1TRPA1 | |
| SCHEMBL31466824 | 0.86 | ESR2 (0.54) | ESR2PTPN5ALOX5APFEN1TRPA1 | |
| SCHEMBL27930441 | 0.84 | ESR2 (0.47) | ESR2PTPN5ALOX5APFEN1CYP3A4 | |
| SCHEMBL2016996 | 0.83 | ESR2 (0.70) | ESR2PTPN5TRPA1TDP1GABRG2 | |
| SCHEMBL29662886 | 0.82 | ESR2 (0.69) | ESR2PTPN5TRPA1HSD17B10GABRG2 | |
| SCHEMBL27895577 | 0.82 | ESR2 (0.69) | ESR2PTPN5TRPA1GABRG2GABRB3 | |
| Water SCHEMBL3178714 | 0.82 | ESR2 (0.69) | ESR2PTPN5TRPA1HSD17B10GABRG2 | |
| SCHEMBL223 | 0.82 | ESR2 (0.69) | ESR2PTPN5TRPA1HSD17B10GABRG2 | |
| Methylamine SCHEMBL3181738 | 0.81 | ESR2 (0.62) | ESR2PTPN5TRPA1CYP3A4HSD17B10 | |
| SCHEMBL28571074 | 0.81 | ESR2 (0.68) | ESR2PTPN5TRPA1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286990-A1 | PROCESS FOR PREPARING IRBESARTAN | DR. REDDY'S LABORATORIES, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7439261-B2 | Process for the preparation of valsartan and intermediates thereof | DIPHARMA S.P.A. (IT) | 2008-10-21 | — | — | US | disclosed |
| US-20060252857-A1 | Aminoaryl-1-3-5-triazines and their use as uv absorbers | SCHAEFER THOMAS | 2006-11-09 | — | — | US | disclosed |
| CN-1795182-A | Aminoaryl-1, 3, 5-triazines and their use as UV absorbers | CIBA SC HOLDING AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| EP-1641768-A2 | AMINOARYL-1-3-5 TRIAZINES AND THEIR USE AS UV ABSORBERS | Ciba SC Holding AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| EP-1533305-A1 | A process for the preparation of valsartan and intermediates thereof | Dipharma S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004106311-A2 | AMINOARYL-1-3-5 TRIAZINES AND THEIR USE AS UV ABSORBERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-12-09 | — | — | WO | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6720317-B1 | 1-NAPHTH-2-YL-1H-PYRAZOLE-5-(4-AMIDINOPHENYL)CARBOXYAMIDE, MULTIPLY SUBSTITUTED; NON AMIDINO ANTICOAGULANTS; HEMOSTATIC AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| EP-0628559-B1 | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF LILLY GMBH (DE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001019798-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-5602137-A | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5602136-A | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5571813-A | Fused pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1996-11-05 | — | — | US | disclosed |
| EP-0628559-A1 | Pyrimidine compounds and their use as pharmaceuticals | Beiersdorf-Lilly GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0572455-A1 | SUBSTITUTED PYRIDINONES AND PYRIMIDINONES AS ANGIOTENSIN II ANTAGONISTS | Astra Pharmaceuticals Limited (GB) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992014714-A1 | SUBSTITUTED PYRIDINONES AND PYRIMIDINONES AS ANGIOTENSIN II ANTAGONISTS | FISONS PLC (GB) | 1992-09-03 | — | — | WO | disclosed |
| EP-0500297-A1 | Substituted pyridinones and pyrimidinones as angiotensin II antagonists | FISONS plc (GB) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252857-A1 | Aminoaryl-1-3-5-triazines and their use as uv absorbers | IK, CRY2, CRY1 | ESR2 1330/4885PTPN5 1498/4885ALOX5AP 2670/4885 |
| US-20090286990-A1 | PROCESS FOR PREPARING IRBESARTAN | AGTR1, PAH, AGT | ESR2 3993/4885PTPN5 913/4885ALOX5AP 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.